𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II study of aziridinylbenzoquinone (AZQ) in patients with central nervous system malignancies: a Southwest Oncology Group study

✍ Scribed by Sarah A Taylor; Joseph D McCracken; Harmon J Eyre; Robert M O'Bryan; Barbara A Neilan

Publisher
Springer US
Year
1985
Tongue
English
Weight
314 KB
Volume
3
Category
Article
ISSN
0167-594X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A Phase II trial of vinorelbine tartrate
A Phase II trial of vinorelbine tartrate in patients with disseminated malignant melanoma and one prior systemic therapy : A Southwest Oncology Group study
✍ Robert P. Whitehead; James Moon; S. Spence McCachren; Evan M. Hersh; Wolfram E. πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 84 KB πŸ‘ 3 views

## Abstract ## BACKGROUND Single‐agent chemotherapy with dacarbazine continues to be the standard of care for the treatment of metastatic melanoma. However, there is a large population of patients who have failed first‐line therapy and might benefit from additional treatment. In the current study,

A phase II evaluation of cisplatin in un
A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: A Southwest Oncology Group Study
✍ Bernard L. Zidar; Stephanie Green; H. I. Pierce; Ralph W. Roach; Stanley P. Balc πŸ“‚ Article πŸ“… 1988 πŸ› Springer US 🌐 English βš– 240 KB

Cisplatin was given intravenously to 35 evaluable patients with unresectable malignant mesothelioma on Southwest Oncology Group (SWOG) Study 8418. Five patients (14.3%) achieved partial response with median response duration of six months (range 2-12 months); eleven patients (31.4%) had stable disea

Phase II study of cisplatin in recurrent
Phase II study of cisplatin in recurrent astrocytomas in adults: A southwest oncology group study
✍ David J. Stewart; Robert M. O'Bryan; Muhyi Al-Sarraf; John J. Costanzi; Noboru O πŸ“‚ Article πŸ“… 1983 πŸ› Springer US 🌐 English βš– 215 KB

Thirty-one evaluable adults with recurrent astrocytomas were treated with Cisplatin 35 mg/m 2 I.V. daily for three days every 3 4 weeks. All patients had previously been irradiated and most had previously received chemotherapy. Approximately half had poor performance status. Two patients experienced